Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs

BACKGROUND: Fibroblast growth factor receptor (FGFR) gene family alterations are found in several cancers, indicating their importance as potential therapeutic targets. The FGFR-tyrosine kinase inhibitor (TKI) pemigatinib has been introduced in the treatment of advanced cholangiocarcinoma and more r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pace, Angelica, Scirocchi, Fabio, Napoletano, Chiara, Zizzari, Ilaria Grazia, Po, Agnese, Megiorni, Francesca, Asquino, Angela, Pontecorvi, Paola, Rahimi, Hassan, Marchese, Cinzia, Ferretti, Elisabetta, Nuti, Marianna, Rughetti, Aurelia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504800/
https://www.ncbi.nlm.nih.gov/pubmed/37715207
http://dx.doi.org/10.1186/s12967-023-04450-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504800/
https://www.ncbi.nlm.nih.gov/pubmed/37715207
http://dx.doi.org/10.1186/s12967-023-04450-7

Ejemplares similares